Request Processed
Your registration request has been processed. We will contact you soon.
Register
First name
Last name
Email
Company
Toggle navigation
Toggle navigation
Login
Register
About
Contact Us
« First
‹ Prev
…
279
280
281
282
283
284
285
286
287
…
Next ›
Last »
The User's Guide to PDUFA V (PDF Attached)
September 7, 2012
GDUFA and BSUFA: Congressional Appropriations Must Kick In For Programs To Start
September 6, 2012
Novartis Tobi Inhaler Wins Advisory Committee Support; Skeptical FDA Review Still An Issue
September 5, 2012
Pediatric Provisions in FDASIA Maintain and Add Incentives, But More Requirements and Timelines Too
September 4, 2012
Split Up HHS? As 2014 Approaches, HHS May Be Too Big To Manage
September 1, 2012
FDA and AIDS: An Overview -- Slide Presentation
September 1, 2012
Novartis Tobi Powder Inhaler Faces Skeptical FDA Review At Upcoming Advisory Committee Review
August 31, 2012
Advisory Committee Tracker: Rare Disease Applications Featured On FDA’s Fall Agenda
August 30, 2012
Teva’s Neupogen-like Product Approved By FDA Goes Through Full BLA, Not Biosimilar Route
August 30, 2012
FDA Advisory Committee Votes for Approval of Abbott’s Humira for Ulcerative Colitis
August 28, 2012
CMS MEDCAC To Reconsider Coverage of Alzheimer’s PET Tracing Agents
August 27, 2012
AIDS Drug Assistance Programs and Health Care Reform: 2013 Will be a Critical Year
August 27, 2012
Abbott’s Humira for Ulcerative Colitis: Additional Trials Pre-Approval a Possibility
August 24, 2012
FDA Publishes Details on Withdrawing Generic Backlog Applications, Two GDUFA Guidance Documents
August 22, 2012
Get Ready for GDUFA: The New Rules for Generic Drug Reviews
August 21, 2012
PDUFA V: Holding the Line on Fees
August 20, 2012
Biosimilars User Fee Act: Up-Front Cost To Sponsors Will Be $200,000 Per IND In FY 2013
August 16, 2012
FDA Inspection Resources and Authority Enhanced By FDASIA
August 14, 2012
GW Obesity Outcomes Paper Points To New Ways To Prove Efficacy; Model For Patient-Centered Regulatory Efforts At FDA
August 14, 2012
Biosimilars Update: Early Analytics the Focus at FDA Pharmaceutical Science Advisory Committee Meeting
August 9, 2012
Qsymia Certified Pharmacy Network Adds Protections Against Generic Regimens
August 8, 2012
REMS in FDASIA: Making Modifications Less Burdensome for Sponsors and REMS Less Burdensome for the Delivery System
July 31, 2012
Senate Hearing On Gray Market Shows Issues Aren’t Black-and-White; Continues Momentum for Track-and-Trace
July 27, 2012
Advisory Committee Votes In Favor of ThromboGenics’ Jetrea for VMA
July 27, 2012
Genentech Lucentis Diabetic Macular Edema Use Headed for Approval: Packaging For Doses, Indications May Delay Action
July 27, 2012
« First
‹ Prev
…
279
280
281
282
283
284
285
286
287
…
Next ›
Last »